What have we learned from CONFIRM Prognostic impl

Authors: Yuka Otaki Reza Arsanjani Heidi Gransar Victor Y Cheng Damini Dey Troy Labounty Fay Y Lin Stephan Achenbach Mouaz AlMallah Matthew J Budoff Filippo Cademartiri Tracy Q Callister HyukJae Chang Kavitha Chinnaiyan Benjamin J W Chow Augustin Delago Martin Hadamitzky Joerg Hausleiter Philipp Kaufmann Erica Maffei Gilbert Raff Leslee J Shaw Todd C Villines Allison Dunning Ricardo C Cury Gudrun Feuchtner YongJin Kim Jonathon Leipsic Daniel S Berman James K Min

Publish Date: 2012/06/12

Volume: 19, Issue: 4, Pages: 787-795

PDF Link

Abstract

Coronary computed tomographic angiography CCTA employing CT scanners of 64detector rows or greater represents a novel noninvasive method for detection of coronary artery disease CAD providing excellent diagnostic information when compared to invasive angiography In addition to its high diagnostic performance prior studies have shown that CCTA can provide important prognostic information although these prior studies have been generally limited to small cohorts at single centers The Coronary CT Angiography Evaluation for Clinical Outcomes An International Multicenter registry or CONFIRM is a large prospective multinational dynamic observational cohort study of patients undergoing CCTA This registry currently represents more than 32000 consecutive adults suspected of having CAD who underwent ≥64detector row CCTA at 12 centers in 6 countries between 2005 and 2009 Based on its large sample size and adequate statistical power the data derived from CONFIRM registry have and will continue to provide key answers to many important topics regarding CCTA Based on its multisite international national design the results derived from CONFIRM should be considered as more generalizable than prior smaller singlecenter studies This article summarizes the current status of several studies from CONFIRM registryDr Min received modest speakers’ bureau and medical advisory board compensation and significant research support from GE Healthcare Dr Achenbach received grant support from Siemens and Bayer Schering Pharma and has served as a consultant for Servier Dr AlMallah received support from the American Heart Association BCBS Foundation of Michigan and Astellas Dr Cademartiri received grant support from GE Healthcare and has served on the Speakers’ Bureau of Bracco and as a consultant for Servier Dr Maffei received grant support from GE Healthcare Dr Chinnaiyan received grant support from Bayer Pharma and Blue Cross Blue Shield Blue Care MI Dr Chow received research and fellowship support from GE Healthcare research support from Pfizer and AstraZeneca and educational support from TeraRecon Dr Hausleiter received a research grant from Siemens Medical Systems Dr Kaufmann received institutional research support from GE Healthcare and grant support from Swiss National Science Foundation Dr Maffei received grant support from GE Healthcare Dr Raff received grant support from Siemens Blue Cross Blue Shield Blue Care MI and Bayer Pharma All other authors have reported that they have no relationships relevant to the contents of this paper to disclose

Keywords: